Continued Chinese dumping in salicylic acid
Chinese dumping persists, pressuring realizations. Management plans to file anti-dumping application by April 2026, but relief may take 6-8 months.
AARTIDRUGS / Q3-FY26 / risks
Keep the risk register visible.
Aarti Drugs · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Slow ramp-up of greenfield facilities
Salicylic acid plant ramp-up slower than expected due to technology changes and quality parameter adjustments, delaying profitability.
Antibiotic demand weakness
Weaker antibiotic demand reduced overall market pool, leading to lower capacity utilization and margin pressure. Management noted this as a key headwind.
High capex despite recent investments
Analyst raised concern about continued high capex (₹150-200 Cr/year) while new plants are still scaling up. Management defended citing smooth Sikar ramp-up and need for oncology investment.